Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Nivolumab in Metastatic NSCLC
NCT03425331Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2018
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, nivolumab in non-small cell lung cancer (NSCLC), sponsored by Dana-Farber Cancer Institute. Started Apr 2018; status: terminated.
02
Drugs
ipilimumabnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03425331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425331.